drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Anti-CD38 IgG1 monoclonal antibody that mediates ADCC, CDC, and ADCP and induces apoptosis of CD38+ clonal plasma cells.
nci_thesaurus_concept_id
C74007
nci_thesaurus_preferred_term
Daratumumab
nci_thesaurus_definition
A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.
drug_mesh_term
Daratumumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Other treatment
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Human IgG1κ monoclonal antibody targeting CD38 on clonal plasma cells; binding triggers immune effector–mediated killing (ADCC, CDC, ADCP) and direct apoptosis, and depletes CD38+ immunosuppressive cells (e.g., Tregs, Bregs, MDSCs), resulting in antitumor activity.
drug_name
Daratumumab
nct_id_drug_ref
NCT06083922